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Introduction
Proteus spp. is widely spread in the environment. 
It may occur in water, soil, manure or sewage, and it is 
also a component of human and animal gastrointesti-
nal tract microbiome (O’Hara et al. 2000; Drzewiecka 
2016). In the current taxonomy of Proteus genus, eight 
species are included: Proteus mirabilis, Proteus vulgaris, 
Proteus penneri, Proteus hauseri, Proteus cibarius, Pro-
teus columbae, Proteus incostans, and Proteus terrae. 
P. mirabilis is the most common species of this genus 
isolated from human infections (Różalski et al. 2007; 
Armbruster and Mobley 2012).
In addition to be a leading cause of urinary tract 
infections (UTI) and chronic wound infections 
(Endimiani et al. 2005), P. mirabilis can also cause 
bloodstream infections. P. mirabilis is found in 1–3% 
of all BSIs (Tumbarello et al. 2012). Other Proteus 
species are rare in BSIs and occur at rates of less than 
0.1 per 100 000 (Laupland et al. 2014).
The most common source of bacteria in BSIs caused 
by P. mirabilis is the urinary tract (UT) (Watanakuna-
korn and Perni 1994). According to Watanakunakorn 
and Perni (1994) and Kim et al. (2003), UT is a source 
of 47.6–52.8% BSIs caused by P. mirabilis (Watana- 
kunakorn and Perni 1994; Kim et al. 2003).
Among infectious diseases, BSIs are a major 
cause of mortality worldwide (Laupland and Church 
2014). Endimiani et al. (2005) found that mortality 
rate attri butable to P. mirabilis BSIs is higher in BSIs 
cases caused by strains with extended spectrum beta-
lactamases (ESBL). The presence of beta-lactamases 
may seriously limit BSIs treatment options. Proteus 
spp. is inherently resistant to polymyxins that are 
used, beside carba penems, in empiric treatments 
of BSIs caused by Gram-negative bacilli. P. mirabilis 
might produce likewise, the AmpC-type cephalospori-
nases and carbapenemases (KPC) (Wang et al. 2014; 
Di Pilato et al. 2016).
The aims of this study were: a) retrospective sus-
ceptibility analysis of Proteus spp. strains isolated from 
BSIs, b) the similarity evaluation of 26 P. mirabilis 
strains isolated from clinical samples collected from 
randomly chosen 11 hospital patients.
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A b s t r a c t
Proteus spp. is an etiological factor of urinary tract and bloodstream infections. The aim of this study was the retrospective analysis of 
susceptibility of Proteus spp. strains isolated from bloodstream infections (BSIs) as well as similarity evaluation of the strains isolated from 
different clinical samples. Proteus spp. strains were isolated in 2009–2017 from hospital patients. Identification was based on the colony’s 
morphology and biochemical or MALDI-TOF MS analyzes. The antibiotic susceptibility test was done using the diffusion method. Biofilm 
formation was evaluated with microplate method using TTC. Bacteremia caused by Proteus spp. was found in 97 patients, mainly secondary 
to urinary tract infection. Most of the strains were susceptible to piperacillin with tazobactam (95.9%) and amikacin (86.7%). Elderly 
patients have a higher risk of mortality after BSIs caused by Proteus spp. A detailed analysis was made for randomly chosen 26 strains iso-
lated from 11 patients with Proteus mirabilis bacteremia. Using PFGE, we found that 10 (90.9%) isolates, collected from different clinical 
specimens of the same patient, were genetically identical.
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Experimental
Materials and Methods
Identification and susceptibility testing of clinical 
Proteus spp. strains. Proteus spp. strains were isolated 
from 2009 to 2017 from patients of the Antoni Jurasz 
University Hospital No 1 in Bydgoszcz, Poland. Basic 
information, i.e., age, sex of patients, and the samples 
collected were determined using laboratory data. Details, 
i.e.: short-term (14  days) mortality after bacteremia, 
length of stay, period from admission to the hospital to 
the onset of Proteus spp. bacteremia, presence of uri-
nal or central venal catheters, the previous surgery, and 
additional diseases were determined by using electronic 
administrative data. We did not find any detailed infor-
mation about 15  patients hospitalized in 2009–2010; 
they were excluded from epidemiological analyzes.
The strains were identified at the Department of 
Microbiology: a) between 2009 and 2011 the identi-
fication was based on colony’s morphology and the 
results of biochemical reactions (API 32E, BioMériuex), 
b) between 2011 and 2014 – on biochemical reaction 
results included in the VITEK GN cards (BioMériuex), 
and c) since 2014 – by using MALDI-TOF MS tech-
nique (Microflex, Bruker).
Susceptibility of Proteus spp. strains was examined: 
in 2009 and 2010 by using the disk diffusion method and 
interpreted in accordance with the Clinical and Labora-
tory Standard Institute (CLSI 2009) recommendation; 
since 2011 – using VITEK AST cards (BioMériuex) and 
interpreted according to the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST 2016). 
The meropenem susceptibility was evaluated since 2016.
Extended-spectrum beta-lactamases (ESBLs) were 
examined according to the CLSI recommendation by 
using the double disk synergic test (DDST).
Primary bacteremia was defined as the bacteremia 
for which no source of infection was documented. 
Bacteremia was defined as secondary when labora-
tory examination showed infection by the same micro-
organism at a distant site in the same time or up to three 
days earlier.
Until the investigation, the selected strains were 
stored in BHI with 20.0% glycerol at 70°C.
Genetic similarity and phenotypic characteriza-
tion of P. mirabilis strains. A detailed analysis was per-
formed for 26 strains isolated from 11 (A-K) randomly 
chosen patients with P. mirabilis bacteremia. Strains 
were isolated from three different samples from four 
patients, and from two different samples – from seven 
patients. Two patients had urethral catheters, and one 
– peripheral venous catheter.
Susceptibility patterns. The susceptibility assays 
of P. mirabilis strains were done using the diffusion 
method according to CLSI recommendation, including 
the following antibiotics in discs (Emapol): trimetho-
prim TRM (5 μg), norfloxacin NOR (10 μg), netilmicin 
NET (30 μg), tobramicin TOB (10 μg), ticarcilin TIC 
(75 μg), amikacin AMK (30 μg), imipenem IMP (10 μg), 
ciprofloxacin CIP (5 μg), cephoperazone CEP (75 μg), 
piperacillin PIP (100 μg), ampicillin AM (10 μg), ticar-
cillin with clavulanic acid TIM (85 μg), cefuroxime 
CXM (30 μg), ampicillin with sulbactam UNA (20 μg), 
gentamicin GEN (10 μg). All results were interpreted 
according to EUCAST (2016).
Biofilm formation. Biofilm formation by 26 P. mi- 
rabilis strains was evaluated based on the method 
described previously by Kwiecińska-Piróg et al. (2013a). 
The method is based on the measurement of absorb-
ance of formazan (dissolution product of 2,3,5-tri phe- 
nyl-tetrazolium chloride, TTC; Avantor; λ = 470 nm) 
(BioTek; Synergy HT Multi-detection; KC4 program). 
The assay was done in three independent repeti-
tions. Two reference strains from the American Type 
Culture Collection (ATCC): Staphylococcus aureus 
ATCC 6538 (strong biofilm former) and Escherichia 
coli ATCC 35218 (weak biofilm former) were used as 
the positive and negative control, respectively.
The A value was calculated based on the average (x) 
and threefold standard deviation (SD) of blank absorb-
ance. The strains which had an absorbance above the A 
value were classified as being able to biofilm formation. 
All strains with an absorbance in the range between 
A  and 2 × A were classified as weak biofilm formers 
(W), in the range between 2 × A and 4 × A – as moder-
ate biofilm formers (M), and above 4 × A – as strong 
biofilm formers (S).
Dienes phenomenon testing. To examine the 
Dienes phenomenon of P. mirabilis strains, single col-
onies, previously cultured on MacConkey Agar, were 
inoculated as points on blood agar plates (Oxoid). The 
strains isolated from the same patient were inoculated 
on one plate. Plates were incubated at 37°C. After 
24  hours, demarcation lines between strains were 
observed. When strains were non-identical, colonies 
were separated by the demarcation line (0.5–2 mm 
wide) (Fig. 1A). When strains were identical – there was 
any demarcation line (Sabbuda et al. 2003) (Fig. 1B).
Genetic similarity of P. mirabilis strains. Genetic 
similarity of Proteus spp. strains was evaluated by 
pulsed field gel electrophoresis (PFGE) using SfiI 
(Fermentas) restriction enzyme cleavage, as previously 
described by Sabbuba et al. (2003) with own modifi-
cations, described by Kwiecińska-Piróg et al. (2013b). 
Comparative analysis was performed using the Quan-
titative One software according to Dice.
Statistical analysis. Statistical analysis was perfor-
med using Statistica 12.5 PL (StatSoft) software. The 
confidence interval for all tests was α = 0.05. To com-
pare variables, the chi2 test with Yates’ correction was 
used, if necessary.
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Results
Proteus spp. blood stream infections. In the exam-
ined time period (2009–2017), BSIs were found in 3956 
cases in 2829 patients. BSIs caused by Proteus spp. were 
confirmed in 98 cases (2.5%) in 97 patients (3.4%). In 
one female patient, secondary urinary tract bacteremia 
was recognized two times with a six-months interval 
between symptoms (Table II).
Proteus spp. bacteremia was caused by P. vulgaris in 
five (5.2%) patients and by P. mirabilis in other patients 
(94.8%). In P. vulgaris bacteremia cases, four strains 
were isolated only from blood samples. One P. vulgaris 
bacteremia was related with a previous isolation of the 
same species strain from a chronic wound.
Median age for all patients with Proteus spp. bac-
teremia was 71 years. We found that 14-day mortality 
ratio of Proteus spp. bacteremia was 28.9%. None of 
P. vulgaris strain was related with short-term mortality. 
We observed that elderly patients have a higher risk of 
mortality (Table I).
During the period analyzed, the most commo-
nly used antibiotic for empiric therapy of BSIs was 
imipenem. Amongst 16 patients treated with imipenem, 
three (20.0%) of them died within 14 days. All P. mirabi-
lis strains isolated from blood samples of these patients 
were susceptible to imipenem. Piperacillin with tazobac-
tam was used in 15 cases of BSIs, and ceftriaxone – in 
13 cases. The 14-days mortality rate for piperacillin with 
tazobactam was 26.7%, and for ceftriaxone – 44.0%.
Primary bacteremia was reported in 40 (40.8%) 
cases. The source of P. mirabilis secondary bacteremia 
was confirmed in 58 (59.2%) cases. In patients with 
secondary bacteremia, the main source of infection was 
the urinary tract (27; 46.6%), wounds of skin or soft 
tissues (14; 24.1%). In nine (9.2%) cases, Proteus spp. 
Age (years), median (min-max) 77.5 (55–94) 67.0 (12–88) 0.0025**
Sex Men, No. (%) 13 (54.2) 33 (55.9) 0.9229
 Women, No. (%) 11 (45.8) 26 (44.1)
Length of stay in hospital (days), median (min-max) 19.5 (1–139) 38 (5–406) 0.0142**
Length of stay in hospital before Proteus spp. BSI (days), 
median (min-max) 9.5 (0–138) 7.5 (0–380) 1.0000**
Primary bacteremia, No. (%) 11 (45.8) 23 (39.0) 0.7420
Secondary bacteremia, No. (%) 13 (54.2) 36 (61.0)
Adequate empiric antibiotic therapy, No. (%) 16 (66.7) 43 (72.9) 0.7648
More than one strain in blood culture, No. (%)  9 (37.5) 20 (34.0) 0.9537
ESBL Proteus spp., No. (%)  4 (16.7) 11 (18.6) 0.9185
Predisposing factors Urinal catheter, No. (%) 18 (75.0) 44 (67.8) 0.8117
 Central Venus Catheter, No. (%) 15 (62.5) 28 (47.5) 0.3168
 Diabetes, No. (%)  7 (29.2) 10 (16.9) 0.3419
 Hospitalization during past half year, No. (%) 13 (54.2) 25 (42.4) 0.4625
 Cancer, No. (%)  3 (12.5)  4 (6.8) 0.6784
 Surgery during past half year, No. (%)  9 (37.5) 33 (55.9) 0.2003
 Cardio-vascular diseases, No. (%)  15 (62.5) 23 (39.0) 0.0879
 Chronic wounds, No. (%)   7 (29.2) 13 (22.0) 0.6849
Table I
Demographic and clinical parameters of patients with Proteus spp. BSIs (n = 83).
* Chi2 test, ** U Mann-Whitney test
Variable Death in 14 days(n = 24)
Survival
(n = 59) p-value*
Fig. 1. The Dienes phenomenon: A) non-identical strains, B) identical strains.
A B
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bacteremia occurred three days prior to isolation of the 
same bacterial species from wound swab, and in seven 
(7.1%) – from urine samples (Table II). One or more 
weeks after P. mirabilis bacteremia, strains of the same 
species were isolated from wound swabs (11; 11.2%), 
central venous catheter samples (5; 5.1%) and urine 
collected by a catheter (5; 5.1%).
All Proteus spp. strains isolated in 2016 and 2017 
(n = 26) were susceptible to meropenem. Most strains 
were susceptible to piperacillin with tazobactam 
(95.9%), ceftazidime (87.8%) and amikacin (86.7%) 
(Table  III). More than half of the strains examined 
(51.0%) were resistant to co-trimoxazole. Resistance 
to ciprofloxacin was reported in 30 (30.6%) strains. All 
40 strains isolated from primary bacteremia cases were 
susceptible to piperacillin with tazobactam. No signifi-
cant differences in the antimicrobial susceptibility of 
strains isolated from primary and secondary bactere-
mia were found (Table III).
ESBLs were found in 18 (18.3%) out of 98 Proteus 
spp. strains. Among all ESBL positive strains, 6 (33.3%) 
were isolated in 2016, and 5 (27.8%) in 2017. None of 
the P. vulgaris strains produced ESBLs.
We compared the antimicrobial drugs susceptibil-
ity of ESBLs-positive (ESBLs(+)) and ESBLs-negative 
(ESBLs(–)) strains using the chi2 test (Fig. 2). Among 
the ESBLs(–) strains, all (n = 80) were susceptible to 
piperacillin with tazobactam. The ESBLs(+) strains 
were more resistant to all penicillins tested with beta-
lactamases inhibitors and cephalosporins. Among the 
ESBLs(+) stra ins, more strains were non-susceptible to 
ciprofloxacin and co-trimoxazole than among ESBLs(–) 
bacteria (Fig. 2).
Susceptibility patterns. The susceptibility patterns 
of isolates from different specimens of the same patient 
were similar, except of the isolate B3 that was geneti-
cally different from B1 and B2 and was more resistant 
to antibiotics than other two isolates collected from the 
same patient. Isolate J2, collected from urine four days 
before the bacteremia, were resistant to trimethoprim 
while J1 were susceptible to this antibiotic (Table IV).
ESBLs were detected in five (19.2%) P. mirabilis 
isolates from two patients (D and G), treated in the 
Intensive Care Unit (G) and the Cardiology Depart-
ment (D). Isolates D1, D2, G1, G2 and G3 had the same 
DNA profiles.
Biofilm formation. The A value was equal to 0.0654, 
based on the formazan absorbance of blank sample. The 
mean values (± SD) of absorbance recorded for biofilms 
formed by the references strains, were as follows: for 
E. coli ATCC 35218 – 0.1031 ± 0.01, and for S. aureus 
ATCC 6538 – 0.6931 ± 0.03. The results obtained for 
clinical P. mirabilis strains were shown in Table IV.
Weak biofilms were formed by 17 (65.4%) isolates, 
moderate biofilms by four (15.4%), and strong by 
five (19.2%) isolates. Most of the strains (8; 72.7%) iso-
lated from blood samples formed weak biofilms. Two 
of three isolates collected from chronic wounds prior 
to bacteremia were able to form stronger biofilms 
than strains collected from blood samples. Two isolates 
2009 12  8 (66.7%) 7 1 0 0 0 1 0 2 0 0 0 1 1 0 0
2010 12  8 (66.7%) 4 0 2 2 0 0 2 0 0 0 0 4 1 2 0
2011 7  4 (57.1%) 1 0 2 0 1 0 2 0 1 1 0 0 1 0 0
2012 4  4 (100.0%) 1 1 1 1 0 0 0 1 0 0 0 0 0 1 0
2013 14  8 (57.1%) 2 2 2 2 0 3 2 1 0 0 0 2 0 1 1
2014 14  9 (64.3%) 5 0 3 1 0 0 2 1 0 0 1 0 0 0 1
2015 9  4 (44.4%) 1 1 2 0 0 0 0 0 0 0 1 1 1 0 0
2016 15  8 (53.3%) 5 1 1 1 0 0 1 1 0 0 1 1 0 0 0
2017 11  5 (45.5%) 1 2 1 0 1 0 0 1 0 0 2 2 1 1 0
Total 98 58 (59.2%) 27 8 14 7 2 4 9 7 1 1 5 11 5 5 2
Table II
The strains isolated from patients with P. mirabilis (n = 93) and P. vulgaris (n = 5) bacteremia.
Year
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from urine samples of catheterized patients formed 
moderate and strong biofilms, while isolates cultured 
from blood sample – weak biofilms. The isolates from 
venal catheters formed weak biofilms, similarly to iso-
lates from blood samples.
Dienes phenomenon results. We found demarca-
tion lines between strains J1 and J2, B1 and B3, and B2 
and B3 (Table IV). Those strains were not genetically 
identical. Strain J1, from urine collected by a catheter, 
formed a stronger biofilm than J2 cultured from the 
blood sample. The B3 strain, cultured from the bedsore 
swab sample, formed a strong biofilm, in contrast to B1 
and B2 isolates that formed a weak biofilm.
Genetic similarity of P. mirabilis isolates. Using 
PFGE we found that isolates collected from different 
clinical specimens were identical in 10 of 11 patients 
(Table IV). In five patients (K, G, H, E, and J), the same 
strains were found in other localizations before the bac-
teremia was confirmed.
Strains J1 and J2, isolated from patient J, were gene-
tically different and formed biofilms with various capa-
city, but they presented similar susceptibility patterns. 
AMC 9  22.5 24 60.0 7 17.5 0.4588 16 27.6 28 48.3 14 24.1 25 25.5 52 53.1 21 21.4
TZP 40 100.0 0 0.0 0 0.0 0.1316 54 93.1 0 0.0 4 6.9 94 95.9 0 0.0 4 4.1
CMX 28  70.0 0 0.0 12 30.0 0.6037 45 77.6 0 0.0 13 22.4 73 74.5 0 0.0 25 25.5
CTX 31  77.5 0 0.0 9 22.5 0.3393 46 79.3 0 0.0 12 20.7 77 78.6 0 0.0 21 21.4
CAZ 35  87.5 2 5.0 3 7.5 0.1697 51 87.9 0 0.0 7 12.1 86 87.8 2 2.0 10 10.2
FEP 32  80.0 2 5.0 6 15.0 0.4254 48 82.8 4 6.9 6 10.3 80 81.6 6 6.1 12 12.2
IMP 30  75.0 8 20.0 2 5.0 0.6062 49 84.5 8 13.8 1 1.7 79 80.6 16 16.3 3 3.1
GEN 29  72.5 1 2.5 10 25.0 0.3662 46 79.3 1 1.7 11 19.0 75 76.5 2 2.0 21 21.4
AMK 33  82.5 3 7.5 4 10.0 0.6311 52 89.7 4 6.9 2 3.4 85 86.7 7 7.1 6 6.1
CIP 24  60.0 1 2.5 15 37.5 0.4336 38 65.5 5 8.6 15 25.9 62 63.3 6 6.1 30 30.6
SXT 20  50.0 0 0.0 20 50.0 0.3165 28 48.3 0 0.0 30 51.7 48 49.0 0 0.0 50 51.0
Table III
Antibacterial agents (Aas) susceptibility of Proteus spp. strains (n = 98) isolated from bacteremia.
* chi2 test – differences in the susceptibility of Proteus spp. strains isolated from primary and secondary bacteremia
S – susceptible, I – intermediate, R – resistant, AMC – amoxicillin + clavulanic acid, TZP – piperacillin with tazobactam,
CXM – cefuroxime, CTX – cefotaxime, CAZ – ceftazidime, FEP – cefepime, IMP – imipenem, GEN – gentamicin, AMK – amikacin,
CIP – ciprofloxacin, SXT – co-trimoxazole
Primary bacteremia
Aas susceptibility
Secondary bacteremia
Aas susceptibility
Total
Aas susceptibility
Aas p*
%n%n%n%n%n%n%nn %n%
RISRISS I R
Fig. 2. Antibiotic susceptibility of ESBLs(+) and ESBLs(–) Proteus spp. strains (n = 98) isolated from bacteremia; p-value of chi2 testing 
between susceptible and non-susceptible (resistant and intermediate) strains; abbreviations of antibiotic names (see Table III).
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The J2 strain was isolated from urine sample four days 
before J1 was cultured from blood sample.
Two strains, B1 and B2, were genetically identical as 
it was shown by their macrorestriction profiles. They 
formed weak biofilms and had the same susceptibil-
ity toward antibiotics. Strain B3, isolated from chronic 
wound swab nine days after confirmation of P. mirabilis 
bacteremia, was similar to B1 and B2, but it formed 
a strong biofilm and was resistant to higher number of 
the antibiotics tested than B1 and B2 isolates.
Discussion
The P. mirabilis is isolated from 1% to 3% of all BSIs 
(Laupland et al. 2007; Sohn et al. 2011). Our study con-
firms these data. We also observed Proteus spp. BSIs in 
2.5% of all BSIs investigated. Among Enterobacterales, 
P. mirabilis is the fourth Gram-negative bacteria species 
after E. coli, Klebsiella pneumoniae, and Enterobacter 
spp. isolated from hospital-acquired BSIs (Sohn et al. 
2011). BSIs are well-known cause of high mortality. We 
found that mortality rate of P. mirabilis BSIs was 28.9%. 
It is similar value to that obtained by Endimiani et al. 
(2005). They found that mortality rate attributable to 
P. mirabilis BSIs was 33.0%.
Laupland et al. (2014) showed that most cases of 
P. mirabilis bacteremia (18; 72.0%) have no documented 
sources and were recognized as primary bacteremia. 
In another seven (28.0%) cases, the urinary tract was 
confirmed to be the source of bacteremia. The oppo-
site results were reported by Sohn et al. (2011). They 
detected primary bacteremia caused by Proteus spp. 
in 32.4% patients. The source of bacteria in secondary 
bacteremia was found mostly (35.1%) in the urinary 
tract and intra-abdominal cavity (21.6%) (Ahn et al. 
2017). Infections of the urinary tract were admitted as 
the main source of BSIs also in the study by Tumbarello 
et al. (2012). They showed this phenomenon in BSIs 
caused by 19 (52.8%) multidrug resistant (MDR) and 
28 (4.4%) non-MDR P. mirabilis strains.
Our data confirms the findings of Sohn et al. (2011). 
In most cases (58; 59.2%), the bacteremia caused by 
P. mirabilis was secondary due to the presence of these 
bacteria in other body sites, particularly in the urinary 
tract (27; 46.6%). In 14 (24.1%) patients, we found P. mi - 
ra bilis in wound swabs. Wound infected by P. mirabilis 
was confirmed as the source of BSIs in the patient of the 
Traumatic Care Unit in India (Endimiani et al. 2005).
Proteus spp. is inherently susceptible to co-trimo-
xazole (trimethoprim-sulfamethoxazole). In the present 
study we found that more than half (51.0%) of the Pro-
teus spp. strains, isolated from patients with bacteremia, 
were resistant to co-trimoxazole. High resistance to co-
trimoxazole was reported also in another paper (Wang 
et al. 2014). Among 158 examined strains isolated from 
blood samples during longitudinal nationwide study 
from the Taiwan Surveillance of Antimicrobial Resist-
ance (TSAR) program, the resistance of P. mirabilis to 
co-trimoxazole was found in 65.2% strains. Similar 
percentage (69.2%) of co-trimoxazole resistance was 
reported also for ESBLs-producing P. mirabilis strains 
isolated from blood samples (Lebeaux et al. 2014). In 
this study, we found that almost all ESBLs(+) strains 
(17; 94.4%) were non-susceptible to co-trimoxazole. 
Lower percentages of resistant strains were found in 
the study by Tumbarello et al. (2012): 33.3% among 
non-MDR, and 30.6% among MDR P. mirabilis strains 
involved in BSIs development.
ESBLs were found by Sohn et al. (2010) in nine 
(24.3%) out of 37 P. mirabilis strains causing bacteremia 
from 2000 to 2009. In our study, we detected ESBLs in 
18.4% P. mirabilis isolates causing bacteremia during 
the period evaluated. The highest number of ESBL-
positive strains was found in 2016 (6; 33.3%). Tum-
barello et al. (2012) noted that ESBLs were confirmed 
in 36 (36.4%) out of 99 P. mirabilis strains causing BSIs. 
MDRs were recorded for 36 (36.6%) strains tested.
Tumbarello et al. (2012) diagnosed P. mirabilis BSIs 
in 103 adult patients. The growth of the strains was 
inhibited by meropenem, amoxicillin with clavulanic 
acid, piperacillin with tazobactam, and amikacin. Ahn 
et al. (2017) confirmed that most P. mirabilis isolates 
from BSIs were susceptible to piperacillin with tazo-
bactam (98.3%) and amikacin (93.5%). In the study by 
Wang et al. (2014), 58.9–87.3% of P. mirabilis strains 
isolated from blood samples were susceptible to gen-
tamicin and amikacin, respectively. This is in agreement 
with the present results. Proteus spp. strains examined 
in this study were mostly susceptible to piperacillin 
with tazobactam (95.3%) and amikacin (86.7%).
Proteus spp. strains were generally susceptible to 
ciprofloxacin (67.1–73.4% of the strains) (Tumbarello 
et al. 2012; Wang et al. 2014). Tumbarello et al. (2012) 
found that susceptibility to ciprofloxacin is rare among 
MDR strains and was showed only by three (8.3%) out 
of 36 strains. Sohn et al. (2010) claim that a correlation 
between ciprofloxacin resistance and ESBLs production 
in P. mirabilis bacteremia may occur. This is in agree-
ment with our results. We found significant differences 
in the susceptibility of ESBLs(+) and ESBLs(–) Proteus 
spp. strains to ciprofloxacin.
Sabbuba et al. (2003) investigated the genetic simi-
larity of P. mirabilis strains isolated from hospitalized 
patients. They confirmed identical DNA profiles of the 
isolates from blood and urine of the same patient. In 
the present study, we report that strains isolated from 
blood samples of 10 out of 11 patients were identical 
with isolates cultured from other clinical specimens. 
The same strains were isolated from various specimens 
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also a few weeks after the bacteremia, that it is because 
of the survival of Proteus spp. strains despite the anti-
biotic treatment. The decrease in the effectiveness 
of antibiotic treatment may be related to the biofilm 
forming ability.
In most cases we observed that strains from clini-
cal samples collected from infections related to bio-
materials were able to form stronger biofilms than 
identical strains from other samples collected from 
these patients. The presence of biomaterials in body 
sites probably promotes biofilm formation, which is in 
agreement with the results obtained by Lebeaux et al. 
(2014) and Di Domenico et al. (2017). We also reported 
that isolates collected from chronic wounds prior to 
bacteremia were able to form stronger biofilms than 
isolates cultured from blood samples.
Conclusions
In most cases bacteremia caused by Proteus spp. was 
secondary to urinary tract infection.
Most of the strains isolated from Proteus spp. BSIs 
were susceptible to piperacillin with tazobactam, third 
generation of cephalosporins, and amikacin.
Elderly patients have a higher risk of mortality in 
consequence of Proteus spp. BSI.
Most strains isolated from blood samples were iden-
tical to isolates cultured from other clinical specimens 
of the same patient.
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